10 mg
Sponsors
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, Ultragenyx Pharmaceutical Inc., Uniwersytet Jagiellonski Collegium Medicum, Centrum Medyczne Ksztalcenia Podyplomowego, Reata Pharmaceuticals Inc., Reata Pharmaceuticals Inc.
Conditions
000 people may be affected by HCM3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years.
HenceAF occurence is even higherAcute ischemic strokeCompulsive Sexual Behaviour DisorderCrohn's diseaseFriedreich's ataxiaGlycogen Storage Disease Type Ia (GSDIa)
Phase 1
Phase 2
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
CompletedCTIS2024-517436-22-00
Start: 2016-07-21End: 2025-06-11Target: 21Updated: 2024-12-05
A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with the specific antidote
RecruitingCTIS2024-518509-17-00
Start: 2022-01-10Target: 300Updated: 2024-12-09
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
CompletedCTIS2023-508750-25-00
Start: 2022-01-11End: 2025-12-22Target: 30Updated: 2026-01-19
The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment due to peripheral arterial disease.
Active, not recruitingCTIS2024-511894-32-00
Start: 2021-08-19Target: 200Updated: 2024-07-01
Pharmacological treatment of compulsive sexual behaviour disorder
WithdrawnCTIS2024-514490-22-00
Target: 410Updated: 2024-09-30
Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and/or duodenum - BETHESDa
RecruitingCTIS2024-519269-23-00
Start: 2024-03-27Target: 138Updated: 2025-07-10
A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week
DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality and mood in
postmenopausal women.
RecruitingCTIS2024-520234-30-00
Start: 2024-11-30Target: 100Updated: 2025-05-13
Phase 4
Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
CompletedCTIS2023-508743-43-00
End: 2025-09-16Target: 725Updated: 2024-09-16
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus-negative myocarditis or inflammatory cardiomyopathy
(IMPROVE-MC).
RecruitingCTIS2024-517484-23-00
Start: 2022-07-26Target: 100Updated: 2024-11-05